Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal cancer screening test, ColoAlert. The test leverages polymerase chain ...

Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...

announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for ...

“Quest is a leader in cancer diagnostics and knows how to scale these innovations to make them broadly accessible to patients in need. With their support, we are positioned to advance commercial ...